Thomas Clozel
Co-Founder & CEO @ Waiv
New York, United States
Thomas Clozel is a seed investor at Waiv in New York focused on Software and Artificial Intelligence. Thomas Clozel co-founded Owkin with Gilles Wainrib and serves as Chief Executive Officer. Mr. Clozel attended Weill Medical College of Cornell University and Icahn School of Medicine at Mount Sinai.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Thomas Clozel invests in
Stages Thomas Clozel invests in
Countries Thomas Clozel invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $2.4M–$10M
Investment Focus
Industry
- Software 4 (36%)
- Artificial Intelligence 3 (27%)
- Health Care 2 (18%)
- Apps 1 (9%)
- FinTech 1 (9%)
Stage
- Seed 9 (82%)
- Pre-Seed 1 (9%)
- Series A 1 (9%)
Country
- France 6 (55%)
- United States 3 (27%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Norbert Health
|
Norbert Health develops a home medical pod that monitors the health of families using contactless sensors. Their product senses key vital signs including heart rate, breathing rate, and temperature, providing a real-time and historical view of the user's health. It was founded in 2019 and headquartered in Brooklyn, New York. | $14M / Series A / Sep 01, 2026 | |
Modern Relay
|
Modern Relay provides context graph for enterprise AI. | $2.9M / Seed / Apr 14, 2026 | |
altrove AI
|
Altrove builds better alternatives to materials that are critical, but insecure. Using the latest advances in AI models and lab automation, altrove designs and builds alternatives to materials we need to reach Net Zero, but for which supply can't meet demand. | $10M / Seed / Oct 31, 2025 | |
Grâce
|
Grâce offers innovative insurance solutions to enhance customer experience and improve process efficiency. | $6.5M / Seed / Apr 03, 2025 | |
|
altrove AI
|
Altrove builds better alternatives to materials that are critical, but insecure. Using the latest advances in AI models and lab automation, altrove designs and builds alternatives to materials we need to reach Net Zero, but for which supply can't meet demand. | $4M / Pre-Seed / Jul 03, 2024 | |
Callyope
|
Callyope is a human-centered technology that can enhance millions of people's lives by increasing the objectivity and responsiveness of brain health monitoring. Callyope develops solutions for remote patient monitoring that assist caregivers in identifying relapses and determining the best course of action. | $2.4M / Seed / Nov 22, 2023 | |
Osium AI
|
Osium AI revolutionize materials development cycles through AI-driven methodologies. | $2.6M / Seed / Nov 22, 2023 | |
Dioxycle
|
Dioxycle is develop electrolyser solutions for carbon dioxide emissions. | Seed / Jan 01, 2022 | |
Resilience
|
Resilience Care is building a software-based solution for cancer treatment providers and patients. By integrating a mobile application with a Remote Patient Monitoring platform, Resilience enhances care by personalizing, humanizing, and improving the care pathway. The mobile application aids individuals affected by cancer in managingtreatment-related side effects and promoting self-care. Simultaneously, the Remote Patient Monitoring platform, classified as a Class IIa medical device, allows healthcare professionals to better understand and improve patient care. | $6M / Seed / Mar 15, 2021 | |
Spot - justspot.io
|
Spot - justspot.io is an information technology & services company. | Seed / Mar 15, 2021 | |
| See all 11 investments → | |||
Co-Investors
About Waiv
Owkin is a French-American startup that uses artificial intelligence to find the right treatment for every patient. Our focus is to use AI to discover and develop better treatments for unmet medical needs, starting with the fight against cancer.They use AI to identify new drug candidates, de-risk and accelerate clinical trials and builddiagnostic tools that improve patient outcomes. Using federated learning, a pioneering collaborative AI framework, Owkin enables medical and biopharma partners to unlock valuable insights from siloed datasets, while protecting patient privacy and securing proprietary data. Owkin was co-founded by Thomas Clozel MD, a clinical research doctor and former assistant professor in clinical onco-hematology, and Gilles Wainrib, a pioneer in the field of machine learning in biology, in 2016.Owkin has raised over $255 million and became a ‘unicorn’ – a startup valued at more than $1 billion – in November 2021 through a $180 million investment from French biopharma company Sanofi.
Waiv Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Darius Meadon
Chief Marketing Officer
|
|||
Jean-Eudes Le Douget
Senior Data Scientist
|
|||
Jeremy Guillon
Machine Learning Engineer
|
|||
Pierre Courtiol
Chief Data Scientist
|
|||
|
Thomas Clozel
Co-Founder & CEO
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Thomas Clozel invest in?
Thomas Clozel invests primarily in Software, Artificial Intelligence and Health Care startups, most often at Seed and Pre-Seed stage. Most of the 11 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Thomas Clozel's check size?
Thomas Clozel typically joins rounds of $2.4M–$10M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Thomas Clozel participates in.
How do I contact Thomas Clozel?
Public channels for Thomas Clozel include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Thomas Clozel last invest?
The most recent investment recorded for Thomas Clozel closed in Sep 2026. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
